International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Paul E. Verweij, Michelle Ananda-Rajah, David Andes, Maiken C. Arendrup, Roger J. Brüggemann, Anuradha Chowdhary, Oliver A. Cornely, David W. Denning, Andreas H. Groll, Koichi Izumikawa, Bart Jan Kullberg, Katrien Lagrou, Johan Maertens, Jacques F. Meis, Pippa Newton, Iain Page, Seyedmojtaba Seyedmousavi, Donald C. Sheppard, Claudio Viscoli, Adilia WarrisJ. Peter Donnelly

Research output: Contribution to journalArticleOtherpeer-review

145 Citations (Scopus)

Abstract

An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome®). In regions with environmental resistance rates of ≥10%, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a panazole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class.

Original languageEnglish
Article number554
Pages (from-to)30-40
Number of pages11
JournalDrug Resistance Updates
Volume21-22
DOIs
Publication statusPublished - 1 Jul 2015
Externally publishedYes

Keywords

  • Aspergillus fumigatus
  • Azole resistance
  • Chronic aspergillosis
  • Invasive aspergillosis
  • Voriconazole

Cite this

Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., ... Donnelly, J. P. (2015). International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 21-22, 30-40. [554]. https://doi.org/10.1016/j.drup.2015.08.001
Verweij, Paul E. ; Ananda-Rajah, Michelle ; Andes, David ; Arendrup, Maiken C. ; Brüggemann, Roger J. ; Chowdhary, Anuradha ; Cornely, Oliver A. ; Denning, David W. ; Groll, Andreas H. ; Izumikawa, Koichi ; Kullberg, Bart Jan ; Lagrou, Katrien ; Maertens, Johan ; Meis, Jacques F. ; Newton, Pippa ; Page, Iain ; Seyedmousavi, Seyedmojtaba ; Sheppard, Donald C. ; Viscoli, Claudio ; Warris, Adilia ; Donnelly, J. Peter. / International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. In: Drug Resistance Updates. 2015 ; Vol. 21-22. pp. 30-40.
@article{506371286f0d45e3b5362dbb0691aedf,
title = "International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus",
abstract = "An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome{\circledR}). In regions with environmental resistance rates of ≥10{\%}, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a panazole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class.",
keywords = "Aspergillus fumigatus, Azole resistance, Chronic aspergillosis, Invasive aspergillosis, Voriconazole",
author = "Verweij, {Paul E.} and Michelle Ananda-Rajah and David Andes and Arendrup, {Maiken C.} and Br{\"u}ggemann, {Roger J.} and Anuradha Chowdhary and Cornely, {Oliver A.} and Denning, {David W.} and Groll, {Andreas H.} and Koichi Izumikawa and Kullberg, {Bart Jan} and Katrien Lagrou and Johan Maertens and Meis, {Jacques F.} and Pippa Newton and Iain Page and Seyedmojtaba Seyedmousavi and Sheppard, {Donald C.} and Claudio Viscoli and Adilia Warris and Donnelly, {J. Peter}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.drup.2015.08.001",
language = "English",
volume = "21-22",
pages = "30--40",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Elsevier",

}

Verweij, PE, Ananda-Rajah, M, Andes, D, Arendrup, MC, Brüggemann, RJ, Chowdhary, A, Cornely, OA, Denning, DW, Groll, AH, Izumikawa, K, Kullberg, BJ, Lagrou, K, Maertens, J, Meis, JF, Newton, P, Page, I, Seyedmousavi, S, Sheppard, DC, Viscoli, C, Warris, A & Donnelly, JP 2015, 'International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus', Drug Resistance Updates, vol. 21-22, 554, pp. 30-40. https://doi.org/10.1016/j.drup.2015.08.001

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. / Verweij, Paul E.; Ananda-Rajah, Michelle; Andes, David; Arendrup, Maiken C.; Brüggemann, Roger J.; Chowdhary, Anuradha; Cornely, Oliver A.; Denning, David W.; Groll, Andreas H.; Izumikawa, Koichi; Kullberg, Bart Jan; Lagrou, Katrien; Maertens, Johan; Meis, Jacques F.; Newton, Pippa; Page, Iain; Seyedmousavi, Seyedmojtaba; Sheppard, Donald C.; Viscoli, Claudio; Warris, Adilia; Donnelly, J. Peter.

In: Drug Resistance Updates, Vol. 21-22, 554, 01.07.2015, p. 30-40.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

AU - Verweij, Paul E.

AU - Ananda-Rajah, Michelle

AU - Andes, David

AU - Arendrup, Maiken C.

AU - Brüggemann, Roger J.

AU - Chowdhary, Anuradha

AU - Cornely, Oliver A.

AU - Denning, David W.

AU - Groll, Andreas H.

AU - Izumikawa, Koichi

AU - Kullberg, Bart Jan

AU - Lagrou, Katrien

AU - Maertens, Johan

AU - Meis, Jacques F.

AU - Newton, Pippa

AU - Page, Iain

AU - Seyedmousavi, Seyedmojtaba

AU - Sheppard, Donald C.

AU - Viscoli, Claudio

AU - Warris, Adilia

AU - Donnelly, J. Peter

PY - 2015/7/1

Y1 - 2015/7/1

N2 - An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome®). In regions with environmental resistance rates of ≥10%, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a panazole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class.

AB - An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome®). In regions with environmental resistance rates of ≥10%, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a panazole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class.

KW - Aspergillus fumigatus

KW - Azole resistance

KW - Chronic aspergillosis

KW - Invasive aspergillosis

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84941317313&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2015.08.001

DO - 10.1016/j.drup.2015.08.001

M3 - Article

C2 - 26282594

AN - SCOPUS:84941317313

VL - 21-22

SP - 30

EP - 40

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

M1 - 554

ER -